Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CERT | Certara, Inc.

Index- P/E118.42 EPS (ttm)0.12 Insider Own1.20% Shs Outstand158.96M Perf Week0.78%
Market Cap2.32B Forward P/E29.92 EPS next Y0.47 Insider Trans-3.71% Shs Float118.17M Perf Month-11.19%
Income19.20M PEG8.62 EPS next Q0.11 Inst Own87.40% Short Float / Ratio5.52% / 8.59 Perf Quarter-18.85%
Sales352.10M P/S6.58 EPS this Y204.40% Inst Trans-1.83% Short Interest6.52M Perf Half Y-39.22%
Book/sh6.90 P/B2.06 EPS next Y4.86% ROA1.20% Target Price19.38 Perf Year7.49%
Cash/sh1.50 P/C9.44 EPS next 5Y13.74% ROE1.80% 52W Range10.60 - 24.96 Perf YTD-11.57%
Dividend- P/FCF31.25 EPS past 5Y55.52% ROI2.10% 52W High-43.07% Beta1.48
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin61.50% 52W Low34.06% ATR0.57
Employees1150 Current Ratio3.40 Sales Q/Q9.30% Oper. Margin12.10% RSI (14)33.30 Volatility2.88% 3.47%
OptionableYes Debt/Eq0.27 EPS Q/Q882.70% Profit Margin5.40% Rel Volume0.45 Prev Close14.41
ShortableYes LT Debt/Eq0.26 EarningsAug 09 AMC Payout0.00% Avg Volume758.82K Price14.21
Recom2.30 SMA20-5.97% SMA50-15.85% SMA200-25.69% Volume307,869 Change-1.39%
Date Action Analyst Rating Change Price Target Change
Aug-22-23Downgrade Jefferies Buy → Hold $24.50 → $17
Aug-10-23Downgrade William Blair Outperform → Mkt Perform
Apr-12-23Initiated Stephens Overweight $28
Apr-03-23Downgrade Barclays Overweight → Equal Weight $25
Dec-14-22Downgrade Robert W. Baird Outperform → Neutral $17 → $19
Sep-08-22Initiated Berenberg Buy $23
Aug-25-22Initiated Credit Suisse Outperform $22
Jul-01-22Initiated Piper Sandler Overweight $28
Jan-11-22Upgrade Jefferies Hold → Buy $31
Aug-05-21Resumed Credit Suisse Neutral $36
Jan-05-21Initiated BofA Securities Buy $41
Sep-19-23 08:15AM
Sep-13-23 05:01AM
Aug-29-23 04:15PM
Aug-23-23 01:43PM
02:41AM Loading…
Aug-22-23 02:41AM
Aug-12-23 08:07AM
Aug-11-23 06:09AM
Aug-10-23 09:41AM
Aug-09-23 04:15PM
Aug-03-23 09:00PM
Aug-02-23 08:55AM
Jul-27-23 09:47AM
Jul-13-23 04:30PM
Jun-02-23 04:15PM
06:50AM Loading…
May-16-23 06:50AM
May-09-23 06:53AM
May-08-23 06:35PM
May-02-23 10:02AM
May-01-23 02:03PM
Apr-28-23 07:15AM
Apr-27-23 08:00AM
Apr-10-23 04:30PM
Apr-06-23 12:19PM
Apr-05-23 12:25PM
12:43PM Loading…
Apr-04-23 12:43PM
Mar-29-23 12:01PM
Mar-28-23 03:00PM
Mar-27-23 11:35AM
Mar-15-23 05:41PM
Mar-14-23 09:40AM
Mar-09-23 12:20PM
Mar-08-23 07:04AM
Mar-07-23 08:00AM
Mar-02-23 07:43AM
Mar-01-23 06:25PM
Feb-27-23 04:30PM
Feb-01-23 04:30PM
Jan-09-23 11:40AM
Jan-04-23 07:31AM
Dec-23-22 06:35PM
Dec-08-22 04:30PM
Nov-26-22 09:01PM
Nov-11-22 04:28PM
Nov-07-22 07:05PM
Nov-02-22 05:00PM
Oct-19-22 08:00AM
Oct-13-22 07:45AM
Aug-31-22 08:00AM
Aug-11-22 04:38PM
Aug-09-22 09:00PM
Aug-05-22 08:00AM
Aug-01-22 03:02PM
Jul-28-22 08:00AM
Jul-25-22 08:00AM
Jul-13-22 08:00AM
Jul-12-22 08:00AM
Jul-09-22 02:05PM
Jun-28-22 08:00AM
Jun-21-22 08:00AM
May-05-22 09:31PM
May-03-22 04:30PM
Apr-20-22 08:00AM
Mar-24-22 09:29AM
Mar-17-22 09:36AM
Mar-01-22 09:30PM
Feb-23-22 04:30PM
Feb-15-22 04:30PM
Feb-08-22 04:30PM
Feb-01-22 01:38PM
Jan-25-22 05:38PM
Jan-14-22 09:38PM
Jan-04-22 12:20PM
Dec-21-21 08:00AM
Dec-17-21 08:38PM
Dec-13-21 08:00AM
Dec-08-21 05:00PM
Dec-02-21 08:00AM
Nov-29-21 04:30PM
Nov-22-21 05:45PM
Nov-17-21 11:27PM
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFSep 11Sale14.6051,224747,870128,883Sep 12 04:26 PM
BROSHY ERANDirectorAug 22Buy15.804,80775,95114,360Aug 23 04:38 PM
BROSHY ERANDirectorAug 21Buy16.101933,1079,553Aug 23 04:38 PM
SMITH PATRICK FPRESIDENT, INTEGRATED DRUG DEVJun 05Sale21.5519,104411,69159,975Jun 06 04:56 PM
BROSHY ERANDirectorMay 23Option Exercise0.009,36009,360May 25 08:50 AM
Crane Rosemary ADirectorMay 23Option Exercise0.009,32409,324May 25 08:45 AM
Killefer NancyDirectorMay 17Option Exercise0.009,067015,498May 18 04:47 PM
CASHMAN JAMES E IIIDirectorMay 17Option Exercise0.009,0670447,849May 18 04:35 PM
WALSH MATTHEW MDirectorMay 17Option Exercise0.009,0670176,968May 19 08:36 AM
Collins CynthiaDirectorMay 17Option Exercise0.009,067015,498May 19 08:34 AM
Traynor Richard M.SVP AND GENERAL COUNSELMay 11Sale20.825,000104,100177,368May 15 04:41 PM
Traynor Richard M.SVP AND GENERAL COUNSELApr 14Sale23.665,000118,300182,368Apr 17 05:07 PM
Virkler DraytonPRESIDENT, REG & ACCESMar 31Option Exercise0.003,990013,581Apr 03 05:44 PM
SHERMAN NICOLETTE DCHIEF HUMAN RESOURCES OFFICERMar 31Option Exercise0.003,990016,798Apr 03 04:53 PM
SMITH PATRICK FPRESIDENT, INTEGRATED DRUG DEVMar 31Option Exercise0.008,646081,973Apr 03 04:51 PM
Traynor Richard M.SVP AND GENERAL COUNSELMar 31Option Exercise0.006,6510189,492Apr 03 04:49 PM
Pedersen Leif EPRESIDENT, SOFTWAREMar 31Option Exercise0.008,6460182,213Apr 03 04:44 PM
Aspbury RobertPRESIDENT, SIMCYPMar 31Option Exercise0.008,6460280,991Apr 03 04:42 PM
Schemick Michael AndrewCHIEF FINANCIAL OFFICERMar 31Option Exercise0.0013,3020527,451Apr 03 04:40 PM
Feehery William FCHIEF EXECUTIVE OFFICERMar 31Option Exercise0.0036,58002,195,285Apr 03 04:35 PM
Traynor Richard M.SVP AND GENERAL COUNSELMar 06Sale21.4510,000214,500184,564Mar 07 04:35 PM
Traynor Richard M.SVP AND GENERAL COUNSELFeb 02Sale20.0015,000300,000194,564Feb 03 04:40 PM
EQT Avatar Parent L.P.10% OwnerDec 08Sale15.0029,954,521449,317,8150Dec 12 04:16 PM
Pedersen Leif EPRESIDENT, SOFTWARENov 22Sale15.5551,223796,518175,500Nov 23 04:54 PM
SLAINE MASON PDirectorNov 15Sale15.57245,7933,826,997660,322Nov 16 04:27 PM
WALSH MATTHEW MDirectorNov 14Sale14.7412,059177,750167,901Nov 15 04:50 PM
SLAINE MASON PDirectorNov 14Sale15.274,20764,241906,115Nov 16 04:27 PM
SMITH PATRICK FPRESIDENT, INTEGRATED DRUG DEVNov 09Sale13.482,38732,17774,859Nov 14 04:33 PM
Virkler DraytonINTERIM PRESIDENT, REG & ACCESSep 30Option Exercise0.0013,595013,595Oct 04 05:05 PM